Share
Thomas Rohrer
Veranova, a global leader in the development and manufacturing of specialty and complex active pharmaceutical ingredients (APIs) for the pharmaceutical and biotech industries, has appointed Thomas Rohrer as Vice President of Bioconjugation.
This strategic hire follows the company’s recent investment to establish cGMP bioconjugation capabilities at its Devens, MA facility.
Bringing over 40 years of experience in biological process development and clinical manufacturing - including three decades in licensed biological manufacturing - Thomas has successfully led the delivery of complex biological programs for both clinical and commercial applications. His expertise spans mammalian, microbial, vaccine, and gene therapy drug substances.
During his 16-year tenure at Lonza, Thomas held leadership roles across multiple locations and departments, including Biopharmaceutical Manufacturing, Antibody Drug Conjugation, Biochemical Technologies, Project Evaluation, and Commercial Development. His extensive career also includes senior roles at Human Genome Sciences (later acquired by GSK), Otsuka America Pharmaceutical, Guidepoint Global LLC, Gentz Biopharmaceutical Consulting LLC, and most recently, Senior Director of Bioconjugate Technology Support at Samsung Biologics.
Thomas earned his Bachelor of Science in Biochemistry from Shepherd University and pursued advanced studies at the University of Maryland’s Graduate School of Engineering in the Department of Chemical and Biochemical Engineering, as well as at the National Institute for Public Health and the Environment in the Netherlands (Rijkes Institute voor de Volksgezondheid).
He has also authored multiple publications and delivered presentations on manufacturing Antibody Drug Conjugates and bioprocesses for biological therapeutics.
With his extensive technical expertise and leadership experience, Thomas will play a pivotal role in expanding Veranova’s bioconjugation capabilities to support innovative therapeutic development.
